Darapladib (Standard)

• Description:

  Darapladib (Standard) is the analytical standard of Darapladib. This product is intended for research and analytical applications. Darapladib (SB-480848) is an orally active, selective and reversible Lp-PLA2 inhibitor (IC50=0.25 nM) . Darapladib can trigger irreversible actions on glioma cell apoptosis and induce cycle arrest. Darapladib can be used in the study of atherosclerosis and cancer[1][2][3][4].

• Product Name Alternative:

  SB-480848 (Standard)

• UNSPSC:

  12352005

• Target:

  Apoptosis; Phospholipase; Reference Standards

• Related Pathways:

  Apoptosis; Metabolic Enzyme/Protease; Others

• Field of Research:

  Cancer; Cardiovascular Disease

• Smiles:

  FC1=CC=C(CSC(N(CC(N(CCN(CC)CC)CC2=CC=C(C3=CC=C(C(F)(F)F)C=C3)C=C2)=O)C4=C5CCC4)=NC5=O)C=C1

• Molecular Formula:

  C36H38F4N4O2S

• Molecular Weight:

  666.77

• References & Citations:

  [1]Blackie JA, et al. The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2. Bioorg Med Chem Lett. 2003 Mar 24;13 (6) :1067-70.|[2]Hu MM, et al. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis inLDLR-deficient mice. Acta Pharmacol Sin. 2011 Oct;32 (10) :1253-1258.|[3]Wang YJ, et al. The selective lipoprotein-associated phospholipase A2 inhibitor darapladib triggers irreversible actions on glioma cell apoptosis and mitochondrial dysfunction. Toxicol Appl Pharmacol. 2020 Sep 1;402:115133. |[4]Riley RF, et al. Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease. IDrugs. 2009 Oct;12 (10) :648-55.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference Standards

• CAS Number:

  [356057-34-6]